2003
Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study
Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study. Breast Cancer Research And Treatment 2003, 79: 391-397. PMID: 12846423, DOI: 10.1023/a:1024038127156.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSerum tumor markersBreast cancerTumor markersTumor differentiationDisease progressionAdvanced breast cancer refractoryElevated serum tumor markersRefractory metastatic breast cancerPeroxisome proliferator-activated receptor γBreast cancer refractoryRefractory breast cancerPhase II studyPercentage of patientsProliferator-activated receptor γDifferent patient populationsCancer refractoryChemotherapy regimenII studyObjective responseSystemic therapyPO QDHormonal regimensHepatic toxicityPatient populationMulticenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Journal Of Clinical Oncology 2003, 21: 999-1006. PMID: 12637463, DOI: 10.1200/jco.2003.05.068.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBexaroteneBreast NeoplasmsDisease ProgressionDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleEstrogen Receptor ModulatorsFemaleHumansMiddle AgedReceptors, EstrogenReceptors, ProgesteroneSurvival AnalysisTamoxifenTetrahydronaphthalenesThyroid HormonesToremifeneTreatment OutcomeConceptsMetastatic breast cancerTamoxifen-resistant patientsPartial responseStable diseaseBreast cancerOral bexaroteneAdverse eventsCommon drug-related adverse eventsDrug-related serious adverse eventsDrug-related adverse eventsMulticenter phase II studyRefractory metastatic breast cancerRetinoid X receptor-selective retinoidEfficacy of bexarotenePhase II studySerious adverse eventsChemotherapy-refractory patientsGroup of patientsReceptor-selective retinoidsHormone-refractory patientsTreatment of patientsCases of pancreatitisDrug-related deathsPreclinical antitumor activityOral agents
1996
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. The Journal Of Infusional Chemotherapy 1996, 6: 211-6. PMID: 9229318.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSymptom Distress ScaleFunctional Living Index-CancerFirst-line settingFirst-line therapyBreast cancerContinuous infusionDisease progressionPrevious phase II studyRefractory metastatic breast cancerAdequate bone marrowContinuous infusion fluorouracilGrade 3 mucositisECOG performance statusMedian overall survivalObjective response ratePhase II studyContinuous intravenous infusionQuality of lifeEvaluable diseaseFLIC scoresInfusion fluorouracilMeasurable diseasePrior chemotherapyIndex cancer